Serotonin 2A receptors contribute to the regulation of risk-averse decisions

[1]  R. Elliott,et al.  Playing it safe but losing anyway—Serotonergic signaling of negative outcomes in dorsomedial prefrontal cortex in the context of risk-aversion , 2013, European Neuropsychopharmacology.

[2]  R. Hertwig,et al.  DAT1 Polymorphism Is Associated with Risk Taking in the Balloon Analogue Risk Task (BART) , 2012, PloS one.

[3]  T. Robbins,et al.  Serotonin Modulates the Effects of Pavlovian Aversive Predictions on Response Vigor , 2012, Neuropsychopharmacology.

[4]  B. Abler,et al.  Modulation of Frontostriatal Interaction Aligns with Reduced Primary Reward Processing under Serotonergic Drugs , 2012, The Journal of Neuroscience.

[5]  Elliot A. Ludvig,et al.  Of Black Swans and Tossed Coins: Is the Description-Experience Gap in Risky Choice Limited to Rare Events? , 2011, PloS one.

[6]  Timothy E. J. Behrens,et al.  Counterfactual Choice and Learning in a Neural Network Centered on Human Lateral Frontopolar Cortex , 2011, PLoS biology.

[7]  Jin Fan,et al.  Common and distinct networks underlying reward valence and processing stages: A meta-analysis of functional neuroimaging studies , 2011, Neuroscience & Biobehavioral Reviews.

[8]  S. Haber.  Neuroanatomy of Reward: A View from the Ventral Striatum , 2011 .

[9]  N. Daw,et al.  Serotonin and Dopamine: Unifying Affective, Activational, and Decision Functions , 2011, Neuropsychopharmacology.

[10]  Colin Camerer,et al.  Dopamine D1 Receptors and Nonlinear Probability Weighting in Risky Choice , 2010, The Journal of Neuroscience.

[11]  P. Cowen,et al.  Diminished Neural Processing of Aversive and Rewarding Stimuli During Selective Serotonin Reuptake Inhibitor Treatment , 2010, Biological Psychiatry.

[12]  P. Dayan,et al.  Opponency Revisited: Competition and Cooperation Between Dopamine and Serotonin , 2010, Neuropsychopharmacology.

[13]  Saori C. Tanaka,et al.  Serotonin Affects Association of Aversive Outcomes to Past Actions , 2009, The Journal of Neuroscience.

[14]  Michael L Platt,et al.  Serotonin shapes risky decision making in monkeys. , 2009, Social cognitive and affective neuroscience.

[15]  M. Roesch,et al.  A new perspective on the role of the orbitofrontal cortex in adaptive behaviour , 2009, Nature Reviews Neuroscience.

[16]  Julie C Price,et al.  Medial prefrontal cortex 5-HT(2A) density is correlated with amygdala reactivity, response habituation, and functional coupling. , 2009, Cerebral cortex.

[17]  George I. Christopoulos,et al.  Neural Correlates of Value, Risk, and Risk Aversion Contributing to Decision Making under Risk , 2009, The Journal of Neuroscience.

[18]  Catherine J. Harmer,et al.  The Role of Serotonin in Nonnormative Risky Choice: The Effects of Tryptophan Supplements on the “Reflection Effect” in Healthy Adult Volunteers , 2009, Journal of Cognitive Neuroscience.

[19]  Timothy Edward John Behrens,et al.  How Green Is the Grass on the Other Side? Frontopolar Cortex and the Evidence in Favor of Alternative Courses of Action , 2009, Neuron.

[20]  R. Shelton,et al.  Elevated 5-HT 2A receptors in postmortem prefrontal cortex in major depression is associated with reduced activity of protein kinase A , 2009, Neuroscience.

[21]  Colin Camerer,et al.  Neural Response to Reward Anticipation under Risk Is Nonlinear in Probabilities , 2009, The Journal of Neuroscience.

[22]  J. Rieskamp.  The probabilistic nature of preferential choice. , 2008, Journal of experimental psychology. Learning, memory, and cognition.

[23]  B. Sahakian,et al.  Acute Tryptophan Depletion in Healthy Volunteers Enhances Punishment Prediction but Does not Affect Reward Prediction , 2008, Neuropsychopharmacology.

[24]  Olaf B. Paulson,et al.  Frontolimbic Serotonin 2A Receptor Binding in Healthy Subjects Is Associated with Personality Risk Factors for Affective Disorder , 2008, Biological Psychiatry.

[25]  M. Lamy.  For Juice or Money: The Neural Response to Intertemporal Choice of Primary and Secondary Rewards , 2007, The Journal of Neuroscience.

[26]  B. Gold,et al.  Functional Dissociation in Frontal and Striatal Areas for Processing of Positive and Negative Reward Information , 2007, The Journal of Neuroscience.

[27]  E. Pehek,et al.  Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. , 2007, Pharmacology & therapeutics.

[28]  Sabrina M. Tom,et al.  The Neural Basis of Loss Aversion in Decision-Making Under Risk , 2007, Science.

[29]  M. Nomura,et al.  Involvement of a polymorphism in the 5-HT2A receptor gene in impulsive behavior , 2006, Psychopharmacology.

[30]  Evan M. Gordon,et al.  Neural Signatures of Economic Preferences for Risk and Ambiguity , 2006, Neuron.

[31]  Thomas E. Nichols,et al.  Non-white noise in fMRI: Does modelling have an impact? , 2006, NeuroImage.

[32]  D. Feinberg,et al.  Single‐shot 3D imaging techniques improve arterial spin labeling perfusion measurements , 2005, Magnetic resonance in medicine.

[33]  J. O'Doherty,et al.  Reward representations and reward-related learning in the human brain: insights from neuroimaging , 2004, Current Opinion in Neurobiology.

[34]  A. Sirigu,et al.  The Involvement of the Orbitofrontal Cortex in the Experience of Regret , 2004, Science.

[35]  G. Pagnoni,et al.  Human Striatal Responses to Monetary Reward Depend On Saliency , 2004, Neuron.

[36]  Claus Svarer,et al.  Quantification of 5-HT2A Receptors in the Human Brain Using [18F]Altanserin-PET and the Bolus/Infusion Approach , 2003, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[37]  R Turner,et al.  Optimized EPI for fMRI studies of the orbitofrontal cortex , 2003, NeuroImage.

[38]  C. Carter,et al.  Tryptophan Depletion Alters the Decision-Making of Healthy Volunteers through Altered Processing of Reward Cues , 2003, Neuropsychopharmacology.

[39]  R. Glennon,et al.  Ketanserin and spiperone as templates for novel serotonin 5-HT(2A) antagonists. , 2002, Current topics in medicinal chemistry.

[40]  H. McFarlane,et al.  M100,907, a selective 5-HT2A antagonist, attenuates dopamine release in the rat medial prefrontal cortex , 2001, Brain Research.

[41]  G H Glover,et al.  Image‐based method for retrospective correction of physiological motion effects in fMRI: RETROICOR , 2000, Magnetic resonance in medicine.

[42]  D. Charney,et al.  PET quantification of 5-HT2A receptors in the human brain: a constant infusion paradigm with [18F]altanserin. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[43]  T. Robbins,et al.  Choosing between Small, Likely Rewards and Large, Unlikely Rewards Activates Inferior and Orbital Prefrontal Cortex , 1999, The Journal of Neuroscience.

[44]  P. Bandettini,et al.  QUIPSS II with thin‐slice TI1 periodic saturation: A method for improving accuracy of quantitative perfusion imaging using pulsed arterial spin labeling , 1999, Magnetic resonance in medicine.

[45]  T. Robbins,et al.  Dissociable Deficits in the Decision-Making Cognition of Chronic Amphetamine Abusers, Opiate Abusers, Patients with Focal Damage to Prefrontal Cortex, and Tryptophan-Depleted Normal Volunteers: Evidence for Monoaminergic Mechanisms , 1999, Neuropsychopharmacology.

[46]  H. Farmer.  A new perspective. , 1988, The Journal of the Florida Medical Association.

[47]  E. Boddeke,et al.  Characterization of flufylline, fluprofylline, ritanserin, butanserin and R 56413 with respect to in‐vivo α1‐, α2‐ and 5‐HT2‐receptor antagonism and in‐vitro affinity for α1‐, α2‐ and 5‐HT2‐receptors: comparison with ketanserin , 1986 .

[48]  E. Boddeke,et al.  Characterization of flufylline, fluprofylline, ritanserin, butanserin and R 56413 with respect to in-vivo alpha 1-,alpha 2- and 5-HT2-receptor antagonism and in-vitro affinity for alpha 1-,alpha 2- and 5-HT2-receptors: comparison with ketanserin. , 1986, The Journal of pharmacy and pharmacology.

[49]  A. Tversky,et al.  Prospect theory: analysis of decision under risk , 1979 .

[50]  E. Rowland.  Theory of Games and Economic Behavior , 1946, Nature.

[51]  M 100 , 907 , a selective 5-HT antagonist , attenuates dopamine release 2 A in the rat medial prefrontal cortex , .